These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35027037)

  • 1. An exploration of immunohistochemistry-based prognostic markers in patients undergoing curative resections for colon cancer.
    Bennedsen ALB; Cai L; Hasselager RP; Özcan AA; Mohamed KB; Eriksen JO; Eiholm S; Bzorek M; Fiehn AK; Hviid TVF; Gögenur I
    BMC Cancer; 2022 Jan; 22(1):62. PubMed ID: 35027037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of cancer stem-like cell markers SOX2 and CD133 in stage III colon cancer is modified by expression of the immune-related markers FoxP3, PD-L1 and CD3.
    Miller TJ; McCoy MJ; Hemmings C; Bulsara MK; Iacopetta B; Platell CF
    Pathology; 2017 Dec; 49(7):721-730. PubMed ID: 29102042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.
    den Uil SH; de Wit M; Slebos RJC; Delis-van Diemen PM; Sanders J; Piersma SR; Pham TV; Coupé VMH; Bril H; Stockmann HBAC; Jimenez CR; Meijer GA; Fijneman RJA
    Eur J Cancer; 2021 Feb; 144():91-100. PubMed ID: 33341450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of PD-L1 expression is associated with EMAST, density of peritumoral T-cells and recurrence-free survival in operable non-metastatic colorectal cancer.
    Watson MM; Lea D; Gudlaugsson E; Skaland I; Hagland HR; Søreide K
    Cancer Immunol Immunother; 2020 Aug; 69(8):1627-1637. PubMed ID: 32314040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients.
    Wyss J; Dislich B; Koelzer VH; Galván JA; Dawson H; Hädrich M; Inderbitzin D; Lugli A; Zlobec I; Berger MD
    Clin Colorectal Cancer; 2019 Mar; 18(1):e20-e38. PubMed ID: 30389315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.
    Gabrielson A; Wu Y; Wang H; Jiang J; Kallakury B; Gatalica Z; Reddy S; Kleiner D; Fishbein T; Johnson L; Island E; Satoskar R; Banovac F; Jha R; Kachhela J; Feng P; Zhang T; Tesfaye A; Prins P; Loffredo C; Marshall J; Weiner L; Atkins M; He AR
    Cancer Immunol Res; 2016 May; 4(5):419-30. PubMed ID: 26968206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Prognostic Role of Mismatch Repair Status and CDX-2 Expression with Inflammatory Markers and Pathological Risk Factors in Stage II and III Colon Cancer: Multicenter Real-Life Data.
    Aydin SG; Olmez OF; Selvi O; Geredeli C; Ozden F; Bilici A; Acikgoz O; Karci E; Kutlu Y; Hamdard J; Aydin A
    J Gastrointest Cancer; 2024 Mar; 55(1):227-236. PubMed ID: 37347353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue-Infiltrating Lymphocytes as a Predictive Factor for Recurrence in Patients with Curatively Resected Colon Cancer: A Propensity Score Matching Analysis.
    Chan LF; Sadahiro S; Suzuki T; Okada K; Miyakita H; Yamamoto S; Kajiwara H
    Oncology; 2020; 98(10):680-688. PubMed ID: 32526753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.
    Derangère V; Lecuelle J; Lepage C; Aoulad-Ben Salem O; Allatessem BM; Ilie A; Bouché O; Phelip JM; Baconnier M; Pezet D; Sebbagh V; Terrebonne E; Bouard G; Jooste V; Bouvier AM; Molimard C; Monnien F; Gonzalez D; Le Malicot K; Rageot D; Truntzer C; Bibeau F; Ghiringhelli F;
    Eur J Cancer; 2022 Sep; 172():221-230. PubMed ID: 35785606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment.
    Roumiguié M; Compérat E; Chaltiel L; Nouhaud FX; Verhoest G; Masson-Lecomte A; Colin P; Audenet F; Houédé N; Larré S; Xylinas E; Brunelle S; Piana-Thomassin J; Cotte J; Pignot G; Neuzillet Y; Rouprêt M
    World J Urol; 2021 Nov; 39(11):4055-4065. PubMed ID: 32666225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Impact of PD-L1 Expression for Survival in Curatively Resected Colon Cancer.
    Jung DH; Park HJ; Jang HH; Kim SH; Jung Y; Lee WS
    Cancer Invest; 2020 Aug; 38(7):406-414. PubMed ID: 32762373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
    Vicier C; Ravi P; Kwak L; Werner L; Huang Y; Evan C; Loda M; Hamid AA; Sweeney CJ
    Prostate; 2021 Jan; 81(1):50-57. PubMed ID: 32986884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
    Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell.
    Wang B; Li F; Guo L; Lu S; Ma J; Ma Y; Meng Y; Wang J; Zhou X; Fu W
    World J Surg Oncol; 2020 Aug; 18(1):196. PubMed ID: 32767974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDX2 and Muc2 immunohistochemistry as prognostic markers in stage II colon cancer.
    Cecchini MJ; Walsh JC; Parfitt J; Chakrabarti S; Correa RJ; MacKenzie MJ; Driman DK
    Hum Pathol; 2019 Aug; 90():70-79. PubMed ID: 31121192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
    Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
    Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed Death Ligand-1 expression in stage II colon cancer - experiences from a nationwide populationbased cohort.
    Eriksen AC; Sørensen FB; Lindebjerg J; Hager H; dePont Christensen R; Kjær-Frifeldt S; Hansen TF
    BMC Cancer; 2019 Feb; 19(1):142. PubMed ID: 30755167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer.
    Calik I; Calik M; Turken G; Ozercan IH; Dagli AF; Artas G; Sarikaya B
    Medicina (Kaunas); 2019 Oct; 55(11):. PubMed ID: 31683723
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.
    Yamashita K; Iwatsuki M; Harada K; Eto K; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Miyamoto Y; Yoshida N; Komohara Y; Ajani JA; Baba H
    Gastric Cancer; 2020 Jan; 23(1):95-104. PubMed ID: 31451991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.